Objective-Peroxisome proliferator-activated receptor-␥ (PPAR␥) has been reported to decrease vascular lesion formation. However, the critical role of vascular smooth muscle cell (VSMC) PPAR␥ in vascular lesion formation following transplantation is not well understood. In this study, we investigated the role of VSMC PPAR␥-mediated signaling in transplantation-associated vascular lesion formation. Methods and Results-Carotid arteries from smooth muscle cell-selective PPAR␥ knockout (SMPG KO) and wild-type mice were transplanted to CBA/CaJ recipient mice. The recipient mice received a control diet or pioglitazone-containing diet. Pioglitazone reduced vascular lesion formation in transplanted wild-type, but not in SMPG KO carotid arteries. Histological analysis suggested that PPAR␥ attenuates vascular lesion formation through antiinflammatory signaling, as evidenced by the increase of intimal inflammatory cells and tumor necrosis factor-␣ expression in SMPG KO allografts. Intravital microscopy revealed increased inflammatory cell rolling and attachment to endothelial cells in small blood vessels of SMPG KO mice following cytokine stimulation. SMPG KO mice, as shown by Western blotting, have elevated vascular cell adhesion molecule-1 (VCAM-1) expression. Furthermore, immunohistochemistry demonstrated SMPG KO allografts have increased VCAM-1.
transcription factor with pleiotropic effects in many cells. PPAR␥ is expressed in cardiovascular cells, including endothelial cells, vascular smooth muscle cells (VSMC), inflammatory cells, and cardiomyocytes. 1 Recent studies have implicated PPAR␥ as having an important role in the regulation of blood pressure. 2 Also, PPAR␥ has functional significance against the development of other cardiovascular diseases, such as cardiac hypertrophy 3, 4 and atherosclerosis. 5, 6 PPAR␥ activation occurs through interaction with natural or synthetic ligands. 1 Thiazolidinediones, a class of insulinsensitizing agents currently used for maintaining normal glycemia in diabetic patients, are synthetic PPAR␥ ligands that regulate gene expression through activation of PPAR␥ signaling cascades. 7 The first clinical trial to study the effects of thiazolidinediones on cardiovascular outcome, the PROactive study, found that pioglitazone was important for secondary prevention of cardiovascular end points. 8 Thus, there is a necessity to further explore the role of PPAR␥ in the cardiovascular system.
A role for PPAR␥ has been implicated in antiinflammatory signaling. 9, 10 PPAR␥ expression potentiates the efficiency of ligands to reduce transcriptional activity of proinflammatory genes. 9 For example, PPAR␥-mediated signaling pathways involve the downregulation of adhesion molecules, 11, 12 proteins that mediate leukocyte rolling on and adhesion to endothelial cells. 13 In the context of clinical allograft transplantation, this has important significance because increased cardiovascular cell adhesion molecule expression is associated with elevated inflammatory responses shortly after organ or vessel transplantation. 14 In patients undergoing transplantation, increased inflammatory signaling has been implicated in allograft rejection. 15 These host immune responses often lead to intragraft vascular lesion formation, 15 considered to be a limiting factor for long-term patient survival. 16 Pioglitazone has been found to significantly reduce proinflammatory pathways responsible for facilitating acute and chronic allograft rejection. 17 However, with respect to allograft transplantation, it is unclear whether pioglitazone-induced antiinflammatory signaling is PPAR␥ dependent. Therefore, it is critical to understand the effect of vascular cell PPAR␥ on inflammatory signaling pathways associated with allograft rejection and transplant-related vascular lesion formation.
In this study, we used a VSMC-selective PPAR␥ knockout (KO) mouse model to study the impact of VSMC PPAR␥ on vascular lesion formation after carotid allograft transplantation. We used an experimental in vivo model for transplant vasculopathy and demonstrated for the first time that VSMC PPAR␥ is an important contributor to the protection against transplant-associated vascular lesion formation. Next, we established a signaling mechanism by which the contribution of PPAR␥ to antiinflammatory signaling in VSMC results in decreased vascular lesion progression. Our novel findings outline the basis for selecting VSMC PPAR␥ as a molecular target for clinical therapeutic intervention following transplantation.
Methods
For a detailed description of methods, please see the supplemental materials (available online at http://atvb.ahajournals.org).
Animals
The animals that served as donors of carotid vessels include (1) VSMC-selective PPAR␥ conditional KO mice (SMPG KO) with a genotype of SM22␣-Cre-knock-in heterozygous and PPAR␥-floxed homozygous (SM22␣ Cre/ϩ /PPAR␥ flox/flox ), and (2) wild-type mice (SM22␣ Cre/ϩ /PPAR␥ floxϪ/floxϪ ). The generation of SMPG KO and wild-type mice has been described previously. 18
Statistical Analysis
Statistical analysis was performed using a standard 1-way ANOVA test. Data are expressed as meanϮSEM; probability values Ͻ0.05 were considered statistically significant.
Results

VSMC-Selective PPAR␥ Deletion Promotes Vascular Lesion Formation Following Transplantation
SMPG KO mice show evidence of deleted PPAR␥ in VSMC, 18 whereas expression patterns of other PPAR iso-forms, PPAR␦ and PPAR␣, are unchanged (Supplemental Figure I ). Therefore, to examine the effects of VSMC PPAR␥ in transplantation-associated vascular lesion formation, we used a transplantation experimental model in which SMPG KO or wild-type mice served as donors of carotid arteries (Supplemental Figure II ). CBA/CaJ mice served as recipients for SMPG KO and wild-type allografts (Supplemental Figure II) . The recipient mice were administered either a pioglitazonecontaining diet or a control diet. Figure 1A shows representative sections of carotid allografts 4 weeks after transplantation. Elastic van Gieson staining provided evidence that SMPG KO allografts had a greater neointimal area and a greater neointimal area/medial area compared with wild-type allografts irrespective of diet ( Figure 1A to 1C) (PϽ0.01, ANOVA). Also, the neointimal area and neointimal area/ medial area in wild-type allografts were further reduced when CBA/CaJ recipient mice were administered a pioglitazonecontaining diet ( Figure 1A to 1C) (PϽ0.05, ANOVA). However, pioglitazone did not decrease the neointimal area or the neointimal area/medial area in SMPG KO allografts ( Figure 1A to 1C). These results demonstrated the effect of pioglitazone on transplantation-associated vascular lesion formation is VSMC PPAR␥ dependent. Moreover, these findings clearly demonstrated the significance of VSMC PPAR␥ in preventing vascular lesion development following transplantation.
VSMC-Selective PPAR␥ Deletion Increases Inflammatory Cell Attachment
Next, we began to elucidate mechanisms by which PPAR␥ attenuates vascular lesion formation in wild-type vessels transplanted to recipient mice. Histological sections of SMPG KO and wild-type allografts were stained with hematoxylin and eosin because hematoxylin confirms the spherical shaped morphology of monocyte nuclei. Representative histological sections demonstrated that the lumens of SMPG KO allografts had greater inflammatory cell attachment when compared with wild-type allografts 2 weeks after carotid artery transplantation (Figure 2A and 2B). Next, analysis of tissue sections after hematoxylin and eosin staining showed that SMPG KO allografts 2 weeks posttransplantation had a greater inflammatory cell count per section compared with wild-type allograft sections ( Figure 2C ) (PϽ0.01, ANOVA). Also, SMPG KO allografts demonstrated greater inflammatory infiltration in the medial layer versus transplanted wild-type vessels (Figure 2A and 2B). Immunohistochemical staining for CD14, a monocyte marker, confirmed the presence of inflammatory cells in the vascular lesions and medial layer of transplanted vessels (Supplemental Figure III) .
Next, histological sections of SMPG KO and wild-type allografts 2 weeks posttransplantation were stained for immunohistochemical detection of tumor necrosis factor-␣ (TNF-␣) expression ( Figure 2D and 2E). Evaluation of immunohistochemical staining revealed a greater increase in TNF-␣ expression for transplanted SMPG KO carotid arteries ( Figure 2F ) (PϽ0.01, ANOVA).
In addition, there was a greater loss of medial smooth muscle cells in SMPG KO vessels 2 weeks after transplantation ( Figure 2A and 2B). Therefore, to investigate the origin of lesional cells following transplantation, carotid arteries from enhanced green fluorescent protein (CAG-EGFP) transgenic mice were transplanted to CBA/CaJ mice and vice versa. When CAG-EGFP carotid arteries were transplanted to CBA/CaJ mice, there was little evidence of EGFP expression in the vascular lesions of CAG-EGFP allografts (Supplemental Figure IV ). Conversely, we found that newly formed vascular lesions of CBA/CaJ allografts were positive for EGFP following transplantation of CBA/CaJ carotid arteries to transgenic CAG-EGFP mice (Supplemental Figure IV) . Our results, consistent with other reports 19 suggested that cells in the vascular lesions of transplanted vessels are mainly derived from the host and not from the graft medial layer. Thus, the loss of medial VSMC in allografts 2 weeks after transplantation indicated that VSMC PPAR␥ inhibits the early proinflammatory response immediately following transplantation. These findings show the critical contribution of VSMC PPAR␥ in attenuating inflammatory cell signaling mechanisms that result in acute organ rejection following transplantation.
VSMC PPAR␥ Deletion Increases Monocyte Adhesion In Vivo
On the basis of our results in Figure 2 , we decided to further demonstrate an inverse relationship between VSMC PPAR␥ expression and proinflammatory cell signaling. Intravital microscopy was used for in vivo visualization of monocyte adhesion to postcapillary venules 4 hours after injection of lipopolysaccharide (LPS) (1 mg/kg) or saline in SMPG KO and wild-type mice ( Figure 3A and Supplemental Videos). The number of cells rolling on SMPG KO mouse venular endothelium per minute was greater compared with wild-type mouse venular endothelium in both LPS-injected and salineinjected studies ( Figure 3B ) (PϽ0.05, ANOVA). In addition, LPS-stimulated SMPG KO mice demonstrated a greater increase in the number of monocytes adhering to the endothelial cell layer of postcapillary venules versus wild-type animals ( Figure 3C ) (PϽ0.01, ANOVA). Taken together, these findings provide further evidence that VSMC PPAR␥ inhibits inflammatory signaling mechanisms involved in increasing monocyte homing and adhesion to the vessel wall.
PPAR␥ Affects Vascular Cell Adhesion Molecule-1 Levels in VSMC
To gain a better understanding of the underlying mechanisms involving VSMC PPAR␥-mediated antiinflammatory signaling, we performed Western blot studies examining the effects of VSMC PPAR␥ on vascular cell adhesion molecule-1 (VCAM-1) expression. For this study, the smooth muscle cell layer from mouse thoracic aortas and primary cultured rat aortic smooth muscle cells (RASMC) were used for determining whether PPAR␥-mediated signaling regulates VCAM-1 expression. Figure 4A is a representative Western blot showing that the vascular smooth muscle tissue of 8-week-old SMPG KO mice had increased VCAM-1 expression compared with tissue of wild-type mice (PϽ0.05, ANOVA). Next, we examined the expression of VCAM-1 in transplanted SMPG KO and wild-type carotid arteries by immunohistochemistry. SMPG KO allografts demonstrated a greater area positive for VCAM-1 at 2 and 4 weeks after . VSMC PPAR␥ deletion increases inflammatory cell attachment. Representative hematoxylin and eosin staining of SMPG KO and wild-type (WT) mouse carotid arteries that were transplanted to CBA/CaJ recipient mice fed a normal diet. Two weeks after transplantation, there was greater inflammatory cell accumulation in the lumens of SMPG KO allografts (B) compared with wild-type allografts (A). nϭ6 for the SMPG KO group and nϭ7 for the wildtype group. The inflammatory cell number for SMPG KO tissue was greater compared with the inflammatory cell number for wildtype tissue (C). Immunohistochemical staining for TNF-␣ expression revealed a greater area positive for cytokine expression in SMPG KO (E and F) compared with wildtype vessels (D and F). nϭ3 for each group in the immunohistochemical study. Two slides per animal were analyzed for TNF-␣ expression. Scale barsϭ50 m. Results are meanϮSEM; probability values Ͻ0.05 were considered statistically significant. transplantation ( Figure 4B and 4C) (PϽ0.05, ANOVA). Next, quantitative Western blot analysis, as shown in Figure  4D , indicated that human interleukin (hIL)-1-stimulated RASMC overexpressed with PPAR␥ had significantly decreased VCAM-1 protein levels compared with hIL-1-stimulated cells treated with green fluorescent protein (PϽ0.05, ANOVA). In contrast, PPAR␥ knockdown by RNA interference (PPAR␥ RNAi) increased VCAM-1 expression versus green fluorescent protein-treated cells (PϽ0.05, ANOVA). Next, pioglitazone reduced hIL-1-stimulated upregulation of VCAM-1 expression in RASMC ( Figure 4E ) (PϽ0.05, ANOVA), further suggesting that VSMC PPAR␥ is critical for inhibiting VCAM-1 expression and proinflammatory signaling. In addition, we found that pioglitazone reduced cytokine-stimulated monocyte chemoattractant protein-1 ex-pression in VSMC from wild-type but not SMPG KO mice (Supplemental Figure V) .
PPAR␥ Knockdown Increases Nuclear Factor-B Activation in VSMC
Previous work demonstrated that VCAM-1 is under the control of nuclear factor-B (NF-B) signaling. 20 Importantly, in hIL-1-stimulated RASMC, we observed that PPAR␥ overexpression reduced (PϽ0.05, ANOVA) and PPAR␥ knockdown by RNA interference increased (PϽ0.05, ANOVA) nuclear protein levels of the NF-B p65 subunit ( Figure 5A ). Neither PPAR␥ overexpression nor PPAR␥ knockdown significantly affected cytosolic p65 protein levels ( Figure 5A ). Furthermore, p65 mRNA expression did not significantly change in hIL-stimulated smooth muscle cells transfected with either a PPAR␥ or PPAR␥ RNA interference vector (Supplemental Figure VI) .
Next, it has been reported that IB kinase, on activation, phosphorylates inhibitor B␣ (IB␣), which consequently results in IB␣ degradation. 21 These events eventually trigger shuttling of p65 from the cytoplasm to nucleus. 21 We found that PPAR␥ knockdown in hIL-1-stimulated RASMC increased both phosphorylated IB kinase and IB␣ ( Figure  5B ) (PϽ0.05, ANOVA). Thus, the findings presented in Figure 5 indicate that VSMC PPAR␥ is involved in abrogating p65 nuclear translocation. Collectively, our results in this study demonstrate the importance of VSMC PPAR␥ in attenuating the proinflammatory response involved in promoting vascular lesion formation following transplantation.
Discussion
There is accumulating evidence indicating PPAR␥ has many functions in the cardiovascular system. In particular, PPAR␥mediated signaling was first shown to reduce vascular injuryinduced lesion formation by inhibiting VSMC proliferation and migration. 22 However, we provide compelling evidence suggesting that the contribution of PPAR␥ in protecting against transplantation-related vascular lesion formation involves antiinflammatory signaling. Our study used VSMC PPAR␥ conditional KO animals and an allograft transplantation model to offer novel insight into the role of VSMC PPAR␥ during intragraft vascular lesion formation. The current study offers the following novel insights: (1) VSMC PPAR␥ signaling is critical for reducing vascular lesion formation seen in transplant arteriosclerosis; (2) VSMC PPAR␥ plays an important role in preventing allograft rejection by reducing proinflammatory signaling; (3) the effects of VSMC PPAR␥-mediated antiinflammatory signaling are manifested, in part, through attenuation of VCAM-1 expression; and (4) a critical contribution is made by VSMC PPAR␥ in mediating pioglitazone-induced reduction of vascular lesion formation following carotid artery transplantation.
A role of PPAR␥ in attenuating vascular lesion formation from balloon-injury and carotid artery ligation has been suggested through the use of PPAR␥ gene delivery and a PPAR␥ mutant mouse model. 22, 23 However, the in vivo models mentioned in the previous reports did not address the role of VSMC-specific PPAR␥ in attenuating transplantationassociated vascular lesion formation. Also, it is important to mention that the experimental vascular lesion formation models reported above 22, 23 focused on PPAR␥ attenuating the VSMC proliferative response as opposed to PPAR␥ promoting antiinflammatory signaling. Furthermore, with respect to studying PPAR␥ mutations, it is unclear whether the dominant negative activity is specific for PPAR␥-mediated signaling as the inhibitory functions of the PPAR␥ mutant have been shown to extend to PPAR␣ and PPAR␦. 24 Thus, dominant-negative PPAR␥ may exhibit alterations of PPAR␣ and PPAR␦ signaling pathways. 24 Also, in the context of a targeted PPAR␥ dominant-negative mutation, absolute deletion of the functionality of PPAR␥ proteins is often difficult to achieve through mutations because a PPAR␥ mutant may still have the ability to interact with other cofactors to facilitate other signaling pathways. 25 In addition, it was reported that tyrosine agonists, high-affinity ligands of PPAR␥, can reverse the molecular defects associated with PPAR␥ dominant-negative mutations. 26 The use of a PPAR␥ cell-selective KO animal model in the present study effectively eliminated both genomic and nongenomic PPAR␥ function. This was advantageous for directly studying the contribution of VSMC PPAR␥ in modulating vascular lesion formation in a carotid artery transplantation model.
Next, this investigation demonstrated that VSMC PPAR␥mediated reduction in transplant-associated vascular lesion formation occurs through antiinflammatory signaling. The use of a transplant vasculopathy experimental model is advantageous for studying immunologic factors influencing vascular lesion progression. 27 Furthermore, the transplant model is ideal for addressing the contribution of VSMC PPAR␥ immunosuppressive signaling mechanisms that reduce vascular lesion development.
Our study is the first to provide direct in vivo evidence that VSMC PPAR␥ deletion results in elevated levels of VCAM-1 following transplantation. Also, our results show that VSMC overexpressed with PPAR␥ have reduced VCAM-1 expression, and this effect is reversed when cells are subjected to RNA interference of PPAR␥. One of the early hallmarks of transplant vasculopathy consists of inflammatory cells attaching to the endothelium and infiltrating the vessel wall. 27 Adhesion molecules, including VCAM-1, are important for inflammatory cell recruitment to the vessel wall and also the communication among inflammatory cells, endothelial cells, and VSMC during a normal immune-mediated response following transplantation. [27] [28] [29] [30] Although several studies suggest that VCAM-1 is produced mainly in endothelial cells, 31, 32 the functional significance of VSMC VCAM-1 should not be understated, particularly because several studies have confirmed VCAM-1 expression in VSMC. For example, cytokine stimulation can dose-and timedependently increase VCAM-1 mRNA and surface expression in cultured VSMC. 33 Also, VCAM-1 expressed in human VSMC from atherosclerotic lesions is found to be associated with leukocyte recruitment. 34 Furthermore, it is of significant interest that experimental models for transplant vasculopathy demonstrate that VCAM-1 is upregulated in medial layer smooth muscle cells. 14, 29 It has been well documented that VCAM-1 expression is regulated by p65, a subunit of NF-B. 20 In the current study, we found that PPAR␥ overexpression reduced and PPAR␥ knockdown increased nuclear p65 protein levels in cultured VSMC. In addition, we observed that loss of PPAR␥ signaling in VSMC caused increased phosphorylation of IB. This has important consequences as phosphorylation leads to proteolytic degradation of IB and subsequent p65 nuclear translocation. 21 Our findings are consistent with previous studies demonstrating the involvement of PPAR familydependent signaling in regulating expression of IB. 35 Taken together, our results suggest that VSMC PPAR␥ inhibition of NF-B transcriptional activity can occur by attenuating p65 nuclear translocation. The elucidation of the precise mechanisms involving PPAR␥-mediated sequestering of cytoplasmic p65 is beyond the scope of this investigation.
It is important to mention that PPAR␥-induced inhibition of p65 nuclear translocation is not the sole mechanism by which PPAR␥ affects NF-B gene activity. For example, there is clear evidence that PPAR␥ transrepresses NF-B inflammatory gene expression in macrophages. 36 Next, PPAR␥ is an activator of antioxidant enzyme expression. 37 Reactive oxygen species are key initiators of NF-B activity, 38 and PPAR␥-induced upregulation of antioxidant genes may inhibit NF-B activity by reducing the level and availability of cellular reactive oxygen species. Thus, we extend the previous work of others 9, 36, 39 by introducing an alternative signaling pathway by which PPAR␥ may negatively regulate NF-B activity. Moreover, it is quite possible that the mechanisms pertaining to PPAR␥-induced inhibition of NF-B transcriptional activity may also be cell specific. Collectively, our in vivo and in vitro findings firmly establish that VSMC PPAR␥ plays an essential role in decreasing NF-B-induced VCAM-1 expression.
The notion that VSMC PPAR␥ ablation results in elevated vascular TNF-␣ expression is further indicative of the importance of PPAR␥ during the observed early inflammatory response following allograft transplantation. In this study, we present evidence suggesting that abolishment of VSMC PPAR␥-mediated inhibition of VCAM-1 will accentuate the number of inflammatory cells infiltrating the vessel wall and result in elevated TNF-␣ expression. Although smooth muscle cells may express TNF-␣, 40 inflammatory cells infiltrating the vessel after transplantation are considered the major contributors of TNF-␣ expression. 41 This is important because TNF-␣ is known to further potentiate posttransplantation inflammatory responses. 41, 42 Thus, the increase in TNF-␣ expression found in transplanted SMPG KO vessels provides further support that VSMC PPAR␥ plays a protective role against the development of transplant vasculopathy by attenuating initial inflammatory-mediated signaling pathways involved in promoting vascular lesion formation. However, it is important to mention that loss of medial smooth muscle cells in allografts can occur following acute rejection, 19, 27 as the eventual increase in VSMC apoptosis can be attributed to infiltration of inflammatory cells. 27 Thus, VSMC PPAR␥, in promoting early antiinflammatory signaling following transplantation, not only decreases allograft vascular lesion formation but may also prolong the survival and function of medial layer smooth muscle cells in donor vessels.
A role for pioglitazone has been demonstrated in attenuating experimental transplantation-associated vascular lesion formation. 17 Our results extend these findings by showing the effects of pioglitazone in reducing vascular lesion formation after transplantation are mediated by VSMC PPAR␥, particularly because SMPG KO allografts do not show any evidence of a decreased lesional area when treated with pioglitazone. Furthermore, our study clearly suggests that the effects of pioglitazone in reducing VCAM-1 expression occur through PPAR␥-dependent signaling in VSMC. However, in immune-mediated responses to transplanted tissue, we should consider that pioglitazone can promote cellular antiinflammatory signaling mechanisms independent of PPAR␥ activation, 1 as the possibility exists for pioglitazone or other PPAR␥ ligands to repress transcription of proinflammatory genes by binding either directly to NF-B or to the promoters of these genes. Nevertheless, our results have important clinical significance, particularly because pioglitazone administration has been shown to improve cardiovascular outcomes. 8 In conclusion, our findings in this study indicate the importance of VSMC PPAR␥ in inhibiting the progression of transplant-associated vascular lesion formation. Given our results demonstrating that VSMC PPAR␥ deletion increases VCAM-1 expression, this study indicates that VSMC PPAR␥ exerts its antiinflammatory properties during the early response to transplantation-induced vascular injury. Thus, we propose that the increase in cellular adhesion molecule expression due to VSMC PPAR␥ deletion promotes increased inflammatory cell adherence to the vessel wall, contributing to greater vascular proinflammatory signaling and increased cytokine production. This is consistent with the literature demonstrating that enhanced cytokine signaling is a major contributor to transplant-associated vascular lesion formation. 15 Although our investigation establishes the critical importance of VSMC PPAR␥ signaling in attenuating lesional development associated with transplant arteriosclerosis, we must acknowledge the pathogeneses of lesion formation in transplant arteriosclerosis, atherosclerosis, and vascular injury are distinct. Therefore, future studies must be conducted to further determine the contribution of VSMC PPAR␥ signaling cascades associated with reduced lesional progression in all experimental models of vascular lesion formation. In summary, our study provides evidence that VSMC PPAR␥ should be considered as a primary target for future pharmacological intervention in transplant arteriosclerosis and other diseases associated with vascular lesion formation.
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